# An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia

> **NCT01175135** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 259 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** PF-02545920
- **DRUG:** PF-02545920
- **DRUG:** Placebo
- **DRUG:** Risperidone

## Key facts

- **NCT ID:** NCT01175135
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 259 (ACTUAL)
- **Last updated:** 2018-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01175135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01175135, "An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01175135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*